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Characteristics of actinic prurigo in Scotland: 24 cases seen between 2001 –2015 
 
This is the peer reviewed version of the following article: ‘Characteristics of actinic prurigo in 
Scotland: 24 cases seen between 2001-2015’, British Journal of Dermatology, which has been 
published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bjd.14444/abstract. This 
article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving. 
 
Dear Editor, Actinic prurigo (AP) is a chronic photosensitivity disease, which is mainly 
described in Amerindians and rarely in Caucasians1-6. The pathogenesis of AP is unclear, 
although familial occurrence is often seen, with a strong association with HLA DR4 and in 
particular HLA DRB1*0407, which is present only rarely in the general population7. 
 
Classically AP is reported to develop in childhood and be characterised by perennial symptoms, 
involvement of distal nose, lower eyelid, conjunctivae, lips and covered sites and be associated 
with abnormal phototesting1,8.  The condition is considered to spontaneously resolve in 
adolescence1,2,8 although late-onset and persistent AP may occur2,4,5,8,9,10. 
 
The Scottish Photobiology Service (SPS), based in Dundee, investigates patients with suspected 
photosensitivity across Scotland.  In order to increase our understanding of this rare condition in 
Caucasian populations, we undertook a retrospective study with Caldicott guardian approval.  We 
included all patients diagnosed and/or investigated with AP in the SPS between April 2001 and 
March 2015.  Information on patient and disease characteristics, investigation findings and 
management were retrieved from the SPS database and from written case records. 
 
Twenty-four patients were identified with AP (0.7% of 3463 patients seen in the SPS during the 
fourteen-year period).  Eighteen (75%) were female and 6 (25%) male.  Most (20 of 21 (95%); 
one patient was Asian and three were unknown) were Caucasian.  Eighteen (75%) patients had 
disease onset at <10 years, with a median age of onset of five (range 1.5-41) years.  The median 
time between onset and diagnosis was six (<1-52) years; with broad age distribution at time of 
diagnosis.  Fourteen (58%) patients had an atopic history and four (17%) had a history of contact 
allergies from previous patch testing.  Eleven (46%) patients had a positive family history of 
photosensitivity (of unknown type) and four (17%) had a family history of atopy.  
 
Most patients (n=18; 75%) were aware of an association with sunlight and (21; 88%) had 
perennial disease activity.  Of those with perennial symptoms, 14 (67%) had summertime 
worsening.  Of the patients who were aware of the association with sunlight, 11 (61%) noticed 
provocation of rash with less than 10 minutes of sun exposure.  Fourteen (78%) patients described 
worsening of symptoms with light through window glass, eight (44%) with light through clothing 
and three (17%) with artificial lighting. 
 
Most patients (n=23; 96%) had facial involvement.  The nasal tip was affected in 14 (58%), lips in 
11 (46%), ears in eight (33%) and conjunctivae in five (21%).  Other affected sites included dorsal 
hands and forearms (15; 63%), neck (7; 29%) and legs (3; 13%).  The main clinical features were 
itch (20; 83%), papules (15; 63%), erythema (11; 46%), vesicles (9; 38%) and scarring (8; 33%) 
(Figure 1).  Ten (42%) patients had involvement of covered sites.  Dermatology life quality index 
questionnaire (DLQI) scores were available in 9 patients; median DLQI 12 (8-27) and 6 
considered that their condition had a ‘very large adverse effect on their life’. 
 
Monochromator phototesting showed a normal action spectrum in nine (38%) cases (Table 1).  
Nine (38%) had abnormal sensitivity to UVA, UVB and visible wavebands and all the remainder 
showed at least UVA sensitivity.  One patient had normal monochromator phototesting on six 
occasions over five years before most recent testing in 2015 showed broadband UVB and UVA 
sensitivity (Figure 1).  UVA provocation testing in 21 cases showed papular reactions in 13 (62%) 
and abnormal erythema in six (29%).  The median narrowband UVB (TL-01) MED was 0.128 
(range <0.025 - >0.39) J/cm2; with abnormally low MEDs (<0.025 J/cm2) in only four cases.  HLA 
typing was undertaken in 20 patients: 18 (90%) were HLA DR4 positive; of whom 12 (67%) were 
DRB1 *0407 positive.  
Seventeen patients were patch tested, with 10 (58%) being positive to a range of common 
allergens. Fifteen patients were photopatch tested, identifying two (13%) with sunscreen allergy.   
IgE levels were raised (>100 kU/L) in eight of 11 (73%).  Histopathology, lupus and porphyria 
screening were non-specific and negative respectively. 
 
General measures of photoprotection, including sunscreens, topical emollients and corticosteroid 
application and sedative anti-histamine use for symptomatic relief of pruritus were advised.  
Treatment responses and data on prognosis were limited as most patients were followed up in 
their local dermatology centre.  Thirteen (65%) described significant benefit with high SPF 
sunscreens; three (15%) slight benefit and four (20%) no improvement in symptoms (data missing 
for four patients).  Five patients required oral corticosteroids; three received azathioprine (two of 
whom obtained no benefit).  Three patients were offered thalidomide but all declined.  Ten 
underwent narrowband UVB desensitisation, with efficacy in four.  One of three patients found 
UVA desensitisation to be of benefit.  Three received PUVA, with efficacy in two.  Over time, five 
had stable disease, five symptomatically improved and 5 subjectively worsened.  Of 10 patients 
who were followed up objectively by phototesting, 6 (60%) showed improvement in 
photosensitivity.   
 
This is the largest recent report of British Caucasian patients with AP, who represented only 0.7% 
of all patients seen in a specialised photodiagnostic unit.  This contrasts with previous studies of 
Amerindian populations where the prevalence was much higher.  In Asian and Mediterranean 
studies, 2-5% of patients investigated in photodiagnostic units had AP11-13.  Thus, our data 
highlight the rarity of this disease in a British Caucasian population. 
 
Our study confirms the female predominance of AP1,2,4 although contrasts with Asian populations 
where it occurs more commonly in males, with late-onset, persistent disease,9,10,12.  We highlight 
the relatively young age of onset for most Caucasian patients with AP, consistent with previous 
observations in Caucasian and Amerindian patients with AP1,8.  However, we also show the 
potential for the disease to first manifest in adulthood, highlighting the importance of considering 
this diagnosis in older patients.  Other Caucasian case series showed a mean age of onset of 14 
years3,4.  However, our case-series highlights an additional difference from AP in Asian 
populations, where onset in middle age is typical9,10,12. 
 
The median time between disease onset and diagnosis was six years.  This delay could be due 
to several factors: disease rarity; the perennial nature of photosensitivity, making it more difficult 
to identify a link with sun exposure; as well as heterogeneity in disease presentation.  For 
example, 88% of patients had perennial disease and 25% were unaware of an association with 
sunlight exposure.  Although facial involvement occurred in 96%, classical sites of lip, conjunctival 
and distal nose involvement were only seen in 58%, 46% and 21% of patients respectively.  
Additionally, 42% of patients had covered site involvement.  Thus, the diagnosis may be 
challenging.  Diagnostic delay was also reported in an Australian study, where mean age of 
disease onset was 14 years, but mean age at diagnosis was 25 years4.  This highlights the 
importance of awareness of this rare condition in order to ensure prompt referral and investigation. 
 
Although we need to be guarded with respect to data interpretation, 58% of patients had a history 
of atopic disease, 73% had elevated total IgE levels and 58% had positive patch testing, 
suggestive of an association with atopy1,3 and contact allergy, which needs further investigation.  
 Monochromator phototesting showed abnormal photosensitivity in most cases.  However, 38% of 
patients had a normal action spectrum.  This appears higher than the report of Addo et al., where 
16% had normal responses1, although is in keeping with Crouch et al., where 40% had normal 
responses4.  This highlights a further diagnostic challenge, illustrated in particular by one patient 
who had normal monochromator phototesting on six occasions over five years before abnormal 
broadband UVA and UVB photosensitivity was ultimately observed (Figure 1).  Hence, repeat 
phototesting is indicated if there is strong suspicion of AP. Most patients with abnormal 
phototesting demonstrated broadband photosensitivity, with UVA wavelengths implicated in all 
cases.  Iterative broadband UVA provocation testing was abnormal in 90%, proving helpful in 
diagnosis, including the patient in whom monochromator phototesting was initially normal.  
Interestingly narrowband UVB MEDs were normal in most patients, supporting the use of 
phototherapy.  
 
Only 46% of patients reported a family history of photosensitivity, which is consistent with reports 
in Caucasian patients but lower than that seen in Amerindian populations1,8.  Our findings confirm 
the diagnostic utility of HLA typing in Caucasian patients, as 90% of patients were HLA DR4 
positive and HLA DRB1*0407 was seen in 60% of those who were HLA tested (67% of those who 
were HLA DR4 positive)14. 
 
Although AP is typically considered to improve/resolve by early adulthood1,2,8, persistent chronic 
disease is reported, particularly in Asian patients, but also in Australian cases4,8-10,12.  Our 
Caucasian patients showed disease persistence in 10 of 15 (66%) cases where follow-up data 
were available, with six of 10 patients followed up with phototesting showing objective 
improvement in photosensitivity.  Furthermore, 42% of our cohort were not diagnosed until >21 
years, with 25% being >40 years old.  Thus, AP may persist into mid-late adulthood, and may not 
resolve in teenage years in most Caucasian patients.  However, follow-up data were limited and 
should not be over-interpreted. 
 
Most (80%) patients reported benefit with high SPF sunscreens, reinforcing the importance of 
perennial photoprotection.  Fourteen patients reported abnormal sensitivity to light through 
window glass and advice on the use of UV-protective film can be useful.  Three patients were 
aware of deterioration after artificial lighting exposure and advice regarding light bulb choices may 
be beneficial.  Narrowband UVB desensitisation was beneficial in 40% and may be an important 
treatment option.  Very few patients required systemic immunosuppression or thalidomide4 as 
most were managed by conservative approaches and phototherapy, which is safer in young 
patients. 
 
For patients in whom DLQI scores were available, a median score of 12 indicates the serious 
adverse impact of this condition on quality of life, with a quarter of patients describing ‘a very large 
negative effect on their life’.  The psychological impact of chronic photosensitivity is increasingly 
recognised and our findings are in keeping with this significant level of adverse impact of 
disease15.  
 
In summary, we have presented the characteristics of the largest recent case-series of AP, seen 
in the Scottish Photobiology Service over a 14-year period. We highlight the rarity of this disease 
in Caucasians and that it can present at any age, may not have the typical disease characteristics 
and may persist, leading to delays in diagnosis. We highlight the importance of considering a 
diagnosis of AP, even if photosensitivity is not immediately apparent.  This should facilitate earlier 
diagnosis and appropriate management of a condition that can otherwise have a profound 
negative impact on quality of life. 
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